|

Iberdomide Clinical Trials

15 actively recruiting trials across 10 locations

▼ -3 trials since June 2026

Also known as: 1323403-33-3, BMS-986382, C25H28N3O5Cl, CC 220, CC-220 +3 more

Pipeline

Phase 1: 6Phase 2: 4Phase 3: 1Phase 1/2: 4

Top Sponsors

  • Hoffmann-La Roche2
  • University of Heidelberg Medical Center1
  • University College, London1
  • Pfizer1
  • Omar Nadeem, MD1

Indications

  • Cancer15
  • Multiple Myeloma9
  • Refractory Multiple Myeloma5
  • Recurrent Multiple Myeloma3
  • Relapsed Multiple Myeloma2

Other4 trials

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Phase 1/2
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
Phase 3
Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
Phase 2
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
Phase 2

San Francisco, California2 trials

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program

Phase 1
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

University of Calfornia, San Francisco

Phase 1

Birmingham, Alabama1 trial

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

University of Alabama at Birmingham

Phase 1

Phoenix, Arizona1 trial

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

Mayo Clinic Hospital in Arizona

Phase 1

Beverly Hills, California1 trial

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

Beverly Hills Cancer Center /ID# 266921

Phase 1

Coral Gables, Florida1 trial

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center

Phase 1

Miami, Florida1 trial

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

University of Miami

Phase 2

Ames, Iowa1 trial

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

Mary Greeley Medical Center

Phase 1/2

Boston, Massachusetts1 trial

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Brigham and Women's Hospital

Phase 1/2

Detroit, Michigan1 trial

Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma

Karmanos Cancer Institute

Phase 2

Rochester, Minnesota1 trial

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

Mayo Clinic in Rochester

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.